Globe Newswire
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK)of its portfolio company EyeBio for a potential value of $3 billion
This acquisition reflects the significant clinical progress achieved with Restoret™, EyeBio’s novel late-phase candidate for diabetic macular edema, as well as a preclinical pipeline targeting retinal diseases -
Restoret anticipated to enter pivotal study for diabetic macular edema in the second half of 2024
- The acquisition by... (continue reading...)
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK)of its portfolio company EyeBio for a potential value of $3 billion
This acquisition reflects the significant clinical progress achieved with Restoret™, EyeBio’s novel late-phase candidate for diabetic macular edema, as well as a preclinical pipeline targeting retinal diseases -
Restoret anticipated to enter pivotal study for diabetic macular edema in the second half of 2024
- The acquisition by... (continue reading...)
MONTRÉAL, May 29, 2024 (GLOBE NEWSWIRE) -- Gildan Activewear Inc. (GIL: TSX and NYSE) (“Gildan” or the “Company”) today announced that the eight director nominees, being all of the existing directors of the Company following the resignation on May 23, 2024 of the prior members of the board of directors, were elected as directors of the Company for the ensuing year by an overwhelming majority of the votes cast by shareholders, in-person, and by proxy, at its... (continue reading...)
VANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- Sable Resources Ltd. ("Sable" or the "Company") (TSXV:SAE | OTCQB: SBLRF) is pleased to announce that it has staked 4,806 hectares of prospective ground in two properties located NW and SE of the Perk Rocky Project in British Columbia.
Dr. Ruben Padilla, President and CEO of Sable stated, “Following the Company’s entering into the option agreement for the Perk Rocky Project, Sable is pursuing... (continue reading...)
VANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- ValOre Metals Corp. (“ValOre”, or the “Company”) (TSX-V: VO, OTCQB: KVLQF, Frankfurt: KEQ0) today provided an update regarding its Hatchet Lake Uranium Property.
Jim Paterson, Chairman and CEO, ValOre Metals Corp. stated: “We have partnered with knowledgeable investors with significant experience in Canada’s uranium exploration sector to help unlock value from our highly prospective Hatchet... (continue reading...)
More Globe Newswire
View Older Stories-
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
-
Host Hotels & Resorts Enters into Agreement to Acquire Turtle Bay Resort in Hawaii
-
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
-
Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer
-
ProKidney to Participate in the Jefferies Global Healthcare Conference
-
The Habit Burger Grill Opens New Drive-Thru in Fresno, Its Fifth Location in the California City
-
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
-
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
-
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
-
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
-
Plum Teams Up with hireEZ to Improve Recruiting Outcomes Through Job Matching
-
Assertio Announces the Appointment of Brendan P. O’Grady as New CEO
-
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
-
Plymouth Industrial REIT to Present at Nareit’s REITweek 2024
-
Lotus Technology Reports Unaudited First Quarter 2024 Financial Results
-
Bitfarms Responds to Unsolicited Proposal from Riot Platforms
-
Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases
-
Cielo Announces Appointment of New Auditor
-
Athira Pharma to Participate in Upcoming June Conferences
-
Dragonfly Energy to Participate in June 2024 Conferences
-
Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024
-
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
-
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
-
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
-
Scorpius Holdings Achieves 359% Year-Over-Year Increase in Revenue for the First Quarter of 2024
-
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
-
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
-
OTC Markets Group Welcomes Verde Agritech Ltd. to OTCQX
-
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
-
OTC Markets Group Welcomes Marpai, Inc. to OTCQX
-
Balchem Corporation to Present at the Wells Fargo Industrials Conference on June 12, 2024
-
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
-
IGM Biosciences to Present at the Jefferies Healthcare Conference
-
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
-
The Habit Burger Grill Opens New Drive-Thru in Fresno, Its Fifth Location in the California City
-
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
-
"Charm of Jiangsu" International Photography Project: Experiencing the Flavor of Happiness
-
"Charm of Jiangsu" International Photography Project: Experiencing the Flavor of Happiness
-
Dimensional Fund Advisors Ltd. : Form 8.3 - INTERNATIONAL PAPER CO - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - HARGREAVES LANSDOWN PLC - Ordinary Shares
-
Castellum, Inc. Announces Leadership Changes
-
Dimensional Fund Advisors Ltd. : Form 8.3 - BARRATT DEVELOPMENTS PLC - Ordinary Shares
-
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
-
Man Group PLC : Form 8.3 - Barratt Developments plc
-
Audit Committee Chair Confirmation
-
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
-
Cybersecurity Skills Shortage Is Ranked as the Biggest Risk to MSPs and Their Clients
-
Global 50 Manufacturing Giant Trusts eGain for Knowledge-Powered Customer Service
-
Radisson Expands Drill Program to 35,000 Metres at the O’Brien Gold Project in Quebec
-
Casey House creates fictitious drug, Stigmavir, to smash HIV stigma within the health care system